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with their normal work. After 3 months, these percentages
changed to 58.5 and 81.8% in the cognitive-behavioral
therapy (CBT) and control groups, respectively.
The relationship between pain and depression in end-stage
renal disease patients is important. The impact of CBT in
alleviating body pain in these patients requires future research.
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Sudden cardiac death and mineral
metabolism in chronic kidney
disease
Pun et al. showed that reductions in the estimated glomerular
ﬁltration rate (eGFR) were associated with an increase in the
risk of sudden cardiac death in a graded fashion in patients
with coronary artery disease. The authors claimed that
decreased eGFR induces many metabolic and physiological
changes that might be responsible for increased sudden
cardiac death in chronic renal failure patients.1 Although the
study is informative, we are especially concerned about the
relationship between calcium, phosphorus, Ca P product,
parathyroid hormone levels, and sudden cardiac death in the
study population. It is well established that abnormalities in
mineral metabolism are apparent early in the course of
chronic kidney disease (CKD). Beginning in CKD stage 3, the
ability of the kidneys to appropriately excrete a phosphate
load is diminished, leading to hyperphosphatemia, elevated
parathyroid hormone, and decreased vitamin D levels.
Furthermore, there is emerging evidence linking some of
these abnormalities (for example, hyperphosphatemia and
hypercalcemia) to the high cardiovascular morbidity and
mortality experienced by nondialyzed patients with CKD.
One of the mechanisms for deranged mineral metabolism
to induce cardiovascular disorders is thought to be the
calciﬁcation of the vascular tree that result in arterial stiffness.
Arterial stiffness of the large arteries has important clinical
consequences: raised systolic blood pressure, increased pulse
pressure, left ventricular hypertrophy, and reduced coronary
perfusion.2,3
Experimental evidence showed that high levels of phos-
phate and/or calcium directly activated genes related to an
osteoblastic phenotype in the smooth muscle cells.4 In
addition, elevated phosphorus and calcium stimulated the
transformation of vascular smooth muscle cells into osteo-
blast-like cells in vitro using cell-culture techniques.5 Besides,
clinical evidence also suggests that high pre-dialysis serum
phosphate is a powerful predictor of sudden cardiac death.6
Since the regular control of calcium, phosphorus, and
parathyroid hormone in chronic renal failure patients is
strongly recommended, if available, the presently informative
results by Pun et al. would have been much more valuable
with the addition of parameters of mineral metabolism in the
adjusted analyses.
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The Authors Reply: We appreciate Drs Afsar and Elsurer
for their interest and comments about our study.1 We agree
that disordered mineral metabolism has been associated
with cardiac risk in hemodialysis patients,2 in those with less
severe chronic kidney disease,3 and in some patients who
lack overt kidney disease.4 We now report available laboratory
data on serum calcium, phosphorus, and parathyroid
hormone (PTH) concentrations obtained within 3 months
prior to cardiac catheterization in the study cohort.
Concurrent PTH data were unavailable on the majority of
patients, but calcium and phosphorus data were available in
46% of patients with glomerular ﬁltration rate (GFR) o15
and in 18% of patients with GFRX15 (Table 1). Calcium and
calcium–phosphorus product had no signiﬁcant relationship
with the composite outcome, but phosphorus had a
signiﬁcant relationship (hazard ratio 1.27, 95% conﬁdence
interval 1.04–1.55) in univariate analysis. However, this
relationship was abolished after accounting for baseline
GFR. Accounting for serum phosphorus did not alter the
relationship between GFR and outcome in an adjusted model.
Therefore, our study ﬁndings could not be explained by
measured abnormalities in mineral metabolism, although the
analysis was limited by missing data.
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